Australië - Engels - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; purified water; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Verenigde Staten - Engels - NLM (National Library of Medicine)

remedyrepack inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 300 mg - reyataz ® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: - reyataz is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. - use of reyataz/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . reyataz is contraindicated:reyataz is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of reyataz capsules or reyataz oral powder [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or lif

Verenigde Staten - Engels - NLM (National Library of Medicine)

remedyrepack inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 200 mg - reyataz ® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: - reyataz is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. - use of reyataz/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . reyataz is contraindicated:reyataz is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of reyataz capsules or reyataz oral powder [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or lif

Verenigde Staten - Engels - NLM (National Library of Medicine)

physicians total care, inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 150 mg - reyataz® (atazanavir sulfate) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. this indication is based on analyses of plasma hiv-1 rna levels and cd4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks duration in antiretroviral-treatment-experienced adult and pediatric patients at least 6 years of age. the following points should be considered when initiating therapy with reyataz: - in study ai424-045, reyataz/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in hiv rna level. this study was not large enough to reach a definitive conclusion that reyataz/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the hiv rna lower limit of detection [see clinical studies (14.2) ]. - the number of baseline primary protease inhibitor mutations affects the virologic response to

Australië - Engels - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: purified water; hydrophobic colloidal silica anhydrous; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Australië - Engels - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; lactose monohydrate; purified water; sodium starch glycollate type a; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Ierland - Engels - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - atazanavir sulphate - capsule, hard - 200 milligram(s) - protease inhibitors; atazanavir

Kenia - Engels - Pharmacy and Poisons Board

atazanavir sulfate and ritonavir tablets 300mg… - tablet - atazanavir sulfate and ritonavir tablets 300mg… - antivirals for systemic use: combinations of

Tanzania - Engels - Tanzania Medicinces & Medical Devices Authority

lupin limited, india - atazanavir , ritonavir - tablets - atazanavir sulfate 300 mg and ritonavir 100 mg

Israël - Engels - Ministry of Health

bristol, myers squibb (israel) limited - atazanavir as sulfate 150 mg - capsules - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.